Combined administration of ethodolac, ascorbic acid and radiotherapy as adjuvant therapies in an extrathoracic desmoid tumor with gross postoperative residual disease; case report and review of the literature.
A 37-year-old man was admitted with an extrathoracic desmoid tumor invading the brachial plexus. Magnetic resonance imaging (MRI) of the thorax demonstrated a 20 x 9 x 14 cm mass in the supraclavicular fossa, axillary fossa and the right side of the chest. It invaded the brachial plexus and circumscribed the subclavian and axillary arteries concentrically. Biopsy revealed desmoid tumor which was resected subtotally with the brachial plexus. The gross residual mass was treated postoperatively with radiotherapy (60 Gy) which resulted in major regression of the mass. Following radiotherapy, ethodolac with ascorbic acid were administered. The tumor was clinically indiscernible 35 months post-radiotherapy. This case shows the high effectiveness of radiotherapy along with less toxic medical treatment modalities in instances where local control is hard to achieve with surgery and highlights the importance of using multidisciplinary treatments to maintain good functional results.
Kilçiksiz
S
S
Department of Radiation Oncology, Atatürk Training and Research Hospital, Izmir, Turkey. sevilkilciksiz@gmail.com
Gökçe
T
T
Somali
I
I
Duransoy
A
A
Aydin
A
A
Yiğit
S
S
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000627:therapeutic use*; D001917:Brachial Plexus; D003131:Combined Modality Therapy; D017308:Etodolac / Q000627:therapeutic use*; D018222:Desmoid Tumors / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D008297:Male; D018365:Neoplasm, Residual; D013899:Thoracic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D035441:Thoracic Wall
D000894:Anti-Inflammatory Agents, Non-Steroidal; D017308:Etodolac; D001205:Ascorbic Acid